`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`
`MYLAN TECHNOLOGIES, INC.
`Petitioner
`v.
`
`NOVEN PHARMACEUTICALS, INC.
`Patent Owner.
`
`_______________
`
`Case No. IPR2018-00174
`U.S. Patent No. 9,730,900
`____________________________________________________________
`
`
`NOVEN PHARMACEUTICALS, INC.’S
`MANDATORY NOTICES UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`4823-5309-6537.1
`
`
`
`
`
`U.S. Patent No. 9,730,900
`IPR2018-00174
`
`Pursuant to 37 C.F.R. § 42.8, Noven Pharmaceuticals, Inc. (“Noven”)
`
`provides this Mandatory Notice within 21 days of service of the Petition (Paper 2)
`
`on December 4, 2017.
`
`I.
`
`Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8 (b)(1):
`
`Noven is the sole owner of U.S. Patent No. 9,730,900 (the “’900 patent”).
`
`Noven Pharmaceuticals, Inc., a wholly owned subsidiary of Hisamitsu
`
`Pharmaceutical Co., Inc., and Hisamitsu Pharmaceutical Co., Inc. are the real
`
`parties-in-interest with respect to the Patent Owner in IPR2018-00174.
`
`II. Related Matters Pursuant to 37 C.F.R. § 42.8 (b)(2):
`
`Noven is aware of the following judicial or administrative matters that
`
`would affect, or be affected by, a decision in the instant proceeding:
`
`The ’900 patent is being asserted in the following patent infringement
`
`lawsuits currently pending in the United States District Court for the District of
`
`Delaware: (1) Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC et al., C.A.
`
`No. 1-17-cv-01429-LPS (D. Del.); and (2) Noven Pharmaceuticals, Inc. v. Mylan
`
`Technologies Inc. et al., C.A. No. 1-17-cv-01777 (D. Del.).
`
`U.S. Patent No. 9,724,310 (“the ’310 patent”) claims benefit of the ’900
`
`patent. The ’310 patent is being asserted in each of the above-listed lawsuits. The
`
`’310 patent also is the subject of a petition for Inter Partes Review, IPR2018-
`
`
`
`1
`
`
`
`U.S. Patent No. 9,730,900
`IPR2018-00174
`
`00173, filed on December 4, 2017.
`
`The ’900 patent is a continuation of U.S. Patent Application No. 12/216,811,
`
`now U.S. Patent No. 8,231,906 (the ’906 patent”). The ’906 patent was asserted in
`
`the following patent infringement lawsuits currently pending in the United States
`
`District Court for the District of Delaware: (1) Noven Pharmaceuticals, Inc. v.
`
`Actavis Laboratories UT Inc., C.A. No. 1-15-cv-00249-LPS (D. Del.); and
`
`(2) Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT Inc., C.A. No. 1-16-
`
`cv-00465 (D. Del.). The ’906 patent also was the subject of the following patent
`
`infringement lawsuits which have terminated: (1) Alvogen Pine Brook LLC v.
`
`Noven Pharmaceuticals, Inc., C.A. No. 1-16-cv-00395-LPS (D. Del.); (2) Noven
`
`Pharmaceuticals, Inc. v. Mylan Technologies Inc. et al., C.A. No. 1-15-cv-00069
`
`(N.D.W. Va.); and (3) Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc. et
`
`al., C.A. No. 1-15-cv-00328 (D. Del.).
`
`The following pending continuing patent application claims the benefit of
`
`the ’906, ’310, and ’900 patents: U.S. Patent Application No. 14/738,255.
`
`III. Lead and Back-Up Counsel Pursuant to 37 C.F.R. §§ 42.8(b)(3):
`
`Noven designates the following Lead and Back-up Counsel. Since the
`
`designated counsel is already counsel of record in the subject patent, a power of
`
`attorney is not being concurrently submitted pursuant to 37 C.F.R. § 42.10(b).
`
`
`
`2
`
`
`
`U.S. Patent No. 9,730,900
`IPR2018-00174
`
`Back-up Counsel
`Jason N. Mock
`Reg. No. 69,186
`
`Foley & Lardner LLP
`3000 K Street, N.W. , Suite 600
`Washington, D.C. 20007-5109
`JMock@foley.com
`Tel: 202-295-4775
`Fax: 202-672-5399
`
`Lead Counsel
`Courtenay C. Brinckerhoff
`Reg. No. 37,288
`
`Foley & Lardner LLP
`3000 K Street, N.W. , Suite 600
`Washington, D.C. 20007-5109
`CBrinckerhoff@foley.com
`Tel: 202-295-4094
`Fax: 202-672-5399
`
`
`
`IV. Service Information Pursuant to 37 C.F.R. §§ 42.8(b)(4):
`
`Pursuant to the requirements of 37 C.F.R. § 42.8(b)(4), Noven may be
`
`served by postal mailing or hand-delivery as follows:
`
`Courtenay C. Brinckerhoff
`Foley & Lardner LLP
`3000 K Street, N.W. , Suite 600
`Washington, D.C. 20007-5109
`
`Noven also consents to service by electronic mail at:
`
`CBrinckerhoff@foley.com
`
`JMock@foley.com and
`
`FIRM-Noven-MylanIPRs@foley.com.
`
`
`
`3
`
`
`
`
`
`
`
`
`
`Any questions concerning this paper may be directed to lead counsel.
`
`U.S. Patent No. 9,730,900
`IPR2018-00174
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: December 21, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Courtenay C. Brinckerhoff /
`Courtenay C. Brinckerhoff
`Registration No. 37,288
`
`Jason N. Mock
`Registration No. 69,186
`
`Counsel for Patent Owner
`Foley & Lardner LLP
`
`4
`
`
`
`U.S. Patent No. 9,730,900
`IPR2018-00174
`
`CERTIFCATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Noven
`
`Pharmaceutical, Inc.’s Mandatory Notices Under 37 C.F.R. § 42.8 was served
`
`on December 21, 2017, by email directed to the attorneys of record for the
`
`Petitioner at the following addresses:
`
`sparmelee@wsgr.com
`mrosato@swgr.com
`jmills@wsgr.com
`
`By: /Courtenay C. Brinckerhoff /
`Courtenay C. Brinckerhoff
`Registration No. 37,288
`
`Jason N. Mock
`Registration No. 69,186
`
`Counsel for Patent Owner
`Foley & Lardner LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`